CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleMarket cap is $2.4B, above the global median of $1.18B
- FinancialsAltman Z-Score 5.67: safe zone
- Interpretations15 currently firing — 15
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
2.40BUSDvs all stocks (USD)
Trailing P/E
13.35xvs Biotechnology peers
Revenue (TTM)
959.90MUSDvs all stocks (USD)
Profit Margin
18.88%vs Biotechnology peers
Beta
0.9250xvs all stocks
52-Week Change
49.28%vs all stocks
Market Capitalization
2.40BUSDvs all stocks (USD)
Enterprise Value
1.90BUSDvs all stocks (USD)
Trailing P/E
13.35xvs Biotechnology peers
Forward P/E
6.17xvs Biotechnology peers
PEG Ratio
0.1510xvs Biotechnology peers
Price to Sales (TTM)
2.50xvs Biotechnology peers
Price to Book (MRQ)
2.40xvs Biotechnology peers
Enterprise to Revenue
1.97xvs Biotechnology peers
Enterprise to EBITDA
7.40xvs Biotechnology peers
Gross Margin
75.81%vs Biotechnology peers
Profit Margin
18.88%vs Biotechnology peers
Operating Margin
34.18%vs Biotechnology peers
Return on Assets (TTM)
11.62%vs Biotechnology peers
Return on Equity (TTM)
20.46%vs Biotechnology peers
Revenue (TTM)
959.90MUSDvs all stocks (USD)
Revenue per Share (TTM)
16.63USDUpdated Sep 27, 2026Quarterly Revenue Growth
30.30%vs Biotechnology peers
Gross Profit (TTM)
723.99MUSDvs all stocks (USD)
EBITDA (TTM)
280.01MUSDvs all stocks (USD)
Net Income (TTM)
181.27MUSDvs all stocks (USD)
Quarterly Earnings Growth (YoY)
89.60%vs Biotechnology peers
Operating Cash Flow (TTM)
355.08MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
182.84MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Sep 27, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Revenue
868.45MUSDFY2025 · Dec 31, 2025Cost of Goods Sold
198.34MUSDFY2025 · Dec 31, 2025Gross Profit
670.11MUSDFY2025 · Dec 31, 2025Operating Income
208.47MUSDvs all stocks (USD)
Pre-tax Income
215.06MUSDFY2025 · Dec 31, 2025Income Tax Expense
56.38MUSDFY2025 · Dec 31, 2025Net Income
158.69MUSDFY2025 · Dec 31, 2025EBIT
229.71MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
255.05MUSDFY2025 · Dec 31, 2025Research & Development
189.59MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
272.05MUSDFY2025 · Dec 31, 2025Non-operating Interest Income
21.92MUSDFY2025 · Dec 31, 2025Non-operating Interest Expense
14.65MUSDFY2025 · Dec 31, 2025EPS (Basic)
2.76USDFY2025 · Dec 31, 2025EPS (Diluted)
2.71USDFY2025 · Dec 31, 2025Basic Shares Outstanding
57.49MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
57.49MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
158.69MUSDFY2025 · Dec 31, 2025Operating Cash Flow
317.93MUSDFY2025 · Dec 31, 2025Free Cash Flow
317.62MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
752.77MUSDFY2025 · Dec 31, 2025Income Tax Paid
19.82MUSDFY2025 · Dec 31, 2025Interest Paid
14.69MUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
158.69MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
25.34MUSDFY2025 · Dec 31, 2025Deferred Taxes (CF)
-7.30MUSDFY2025 · Dec 31, 2025Stock-based Compensation
44.90MUSDFY2025 · Dec 31, 2025Other Non-cash Items
36.29MUSDFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-13.75MUSDFY2025 · Dec 31, 2025Change in Accounts Payable (CF)
3.95MUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
69.83MUSDFY2025 · Dec 31, 2025Capital Expenditures
-310.00KUSDFY2025 · Dec 31, 2025Net Acquisitions
-19.25MUSDFY2025 · Dec 31, 2025Purchase of Investments
-86.15MUSDFY2025 · Dec 31, 2025Sale of Investments
81.06MUSDFY2025 · Dec 31, 2025Other Investing Activity
-15.00MUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
-39.65MUSDFY2025 · Dec 31, 2025Long-term Debt Issuance
0.00USDFY2025 · Dec 31, 2025Long-term Debt Payments
-16.25MUSDFY2025 · Dec 31, 2025Common Stock Repurchase
0.00USDFY2025 · Dec 31, 2025Other Financing Charges
-3.00MUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
-19.25MUSDFY2025 · Dec 31, 2025Shares Outstanding
58.12MSharesUpdated Sep 27, 2026Float Shares
52.09MSharesUpdated Sep 27, 2026Shares Short
4.63MSharesUpdated Sep 27, 2026Short Ratio
5.67daysvs all stocks
Short % of Shares Outstanding
10.62%vs all stocks
% Held by Insiders
11.61%vs all stocks
% Held by Institutions
99.67%vs all stocks
Total Cash (MRQ)
667.79MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
11.47USDUpdated Sep 27, 2026Total Debt (MRQ)
160.19MUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
0.1603xvs Biotechnology peers
Current Ratio (MRQ)
3.48xvs Biotechnology peers
Book Value per Share (MRQ)
17.19USDUpdated Sep 27, 2026Total Assets
1.27BUSDvs all stocks (USD)
Total Current Assets
907.01MUSDFY2025 · Dec 31, 2025Total Liabilities
401.41MUSDFY2025 · Dec 31, 2025Total Non-current Assets
364.62MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
149.28MUSDFY2025 · Dec 31, 2025Total Current Liabilities
252.13MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
752.50MUSDFY2025 · Dec 31, 2025Other Short-term Investments
22.84MUSDFY2025 · Dec 31, 2025Accounts Receivable
96.79MUSDFY2025 · Dec 31, 2025Inventory
5.36MUSDFY2025 · Dec 31, 2025Accounts Payable
17.69MUSDFY2025 · Dec 31, 2025Short-term Debt
20.00MUSDFY2025 · Dec 31, 2025Other Current Liabilities
4.96MUSDFY2025 · Dec 31, 2025Long-term Debt
143.66MUSDFY2025 · Dec 31, 2025Other Non-current Liabilities
5.62MUSDFY2025 · Dec 31, 2025Common Stock (Book)
1.00KUSDFY2025 · Dec 31, 2025Retained Earnings
160.90MUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
870.22MUSDvs all stocks (USD)
52-Week Low
25.52USDUpdated Sep 27, 202652-Week High
43.49USDUpdated Sep 27, 202652-Week Change
49.28%vs all stocks
Beta
0.9250xvs all stocks
50-Day MA
39.08USDUpdated Sep 27, 2026200-Day MA
34.64USDUpdated Sep 27, 2026Avg 10-Day Volume
1.23MSharesUpdated Sep 27, 2026Avg 30-Day Volume
918.59KSharesUpdated Sep 27, 2026Diluted EPS (TTM)
3.09USDUpdated Sep 27, 2026Other Income / Expense
-680.00KUSDFY2025 · Dec 31, 202515 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company financially stable?
MRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total Liabilities
Cash covers most of its debt, with earnings high against its liabilities.
Reads
Multi-Year Cash Increase With FCF And Debt Decrease
Cash up four years running while long-term debt fell for three.
Reads
Multi-Year Debt Decrease With Cash Near Total Debt And Equity
Long-term debt down in each of four years, and cash now covers most or all of what is left.
Reads
How does this company use capital?
Three Asset-Base Ratios Elevated
It gets more sales from its assets than its industry does, and a lot of profit from them too.
Reads
Cash Backing With OCF Coverage And Cash Near Total Debt
Cash on hand covers most or all of its total debt, and cash flow matches reported earnings.
Reads
Cash Backing With Revenue And Income Streaks
Revenue has risen in each of three years, profit in all three, and it holds more cash than debt.
Reads
Working Capital Pattern
What customers owe has grown three years running, while it clears stock quickly and pays suppliers quickly.
Reads
Cash-Flow Ratios Elevated
More of its sales turn into cash than in its industry, and less of that cash is consumed by reinvestment than at most of its peers.
Reads
FCF Ratios Elevated
Its free cash flow is large next to assets and equity, and more of its operating cash reaches it than in its industry.
Reads
Industry-Benchmarked ROA and Margin Elevated
Returns and margins have sat in the top of its industry across five years.
Reads
Industry-Benchmarked Return on Capital Elevated
It earns more on its assets and its equity than its industry, and gets more sales from those assets.
Reads
Multi-Year FCF With Growth And Margin
Three years of positive free cash flow and rising revenue, four of rising equity, and much of its sales turns into cash.
Reads
Revenue Growing With Receivables Growing
Revenue has risen three years, and what customers owe has risen with it.
Reads
ROE, ROA, And Operating ROA Elevated
It earns more on its equity than its industry does, and on its assets too — not on borrowing alone.
Reads
Is this company growing?
Multi-Year Revenue, Profit, And Income Growth
Revenue has risen in each of three years, gross profit in each of four, and it has made a profit in all five.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Financial Health
Altman Z-Score 5.67: safe zoneNotable
Altman Z-Score: 5.67
High earnings qualityNotable
Earnings Quality Score: 0.98
High structural barrier to entryNotable
Barrier to Entry: 0.54
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Market cap is $2.4B, above the global median of $1.18BNotable
Market cap (USD): 2,402,833,575Global Median: 1,180,223,658.953
Revenue is $959.9M, above the global median of $548.88MNotable
Revenue (USD): 959,897,984Global Median: 548,883,780.48
Levered free cash flow is $182.84M, above the global median of $18.73MNotable
Levered free cash flow (USD): 182,835,504Global Median: 18,729,043.027
Companies that share the same coordination system — how they create, deliver, or capture value.
BrightGene Bio-Medical Technology Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Nurix Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Immunome Inc.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Celldex Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Double Medical Technology Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Pharma Research Products Co., Ltd
Tier 1ProductionApproval-Gated PipelineRule
HUTCHMED
Tier 1ProductionApproval-Gated PipelineRule
Sellas Life Sciences Group Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Vera Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Viridian Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Companies that share active interpretations — structural patterns currently present in both stocks.
United States Lime & Minerals Inc.
12 interpretationsMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total LiabilitiesCash Backing With Revenue And Income StreaksFCF Ratios ElevatedROE, ROA, And Operating ROA ElevatedCash-Flow Ratios ElevatedMulti-Year Cash Increase With FCF And Debt DecreaseRevenue Growing With Receivables GrowingMulti-Year Revenue, Profit, And Income GrowthWorking Capital PatternIndustry-Benchmarked ROA and Margin ElevatedMulti-Year FCF With Growth And MarginMulti-Year Debt Decrease With Cash Near Total Debt And Equity
Catalyst Pharmaceuticals Inc.
12 interpretationsMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total LiabilitiesCash Backing With Revenue And Income StreaksFCF Ratios ElevatedROE, ROA, And Operating ROA ElevatedCash-Flow Ratios ElevatedRevenue Growing With Receivables GrowingMulti-Year Revenue, Profit, And Income GrowthIndustry-Benchmarked Return on Capital ElevatedIndustry-Benchmarked ROA and Margin ElevatedThree Asset-Base Ratios ElevatedMulti-Year FCF With Growth And MarginMulti-Year Debt Decrease With Cash Near Total Debt And Equity
NVIDIA Corporation
11 interpretationsMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total LiabilitiesCash Backing With Revenue And Income StreaksFCF Ratios ElevatedROE, ROA, And Operating ROA ElevatedCash-Flow Ratios ElevatedRevenue Growing With Receivables GrowingMulti-Year Revenue, Profit, And Income GrowthIndustry-Benchmarked Return on Capital ElevatedIndustry-Benchmarked ROA and Margin ElevatedThree Asset-Base Ratios ElevatedMulti-Year FCF With Growth And Margin